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Abstract: Protamine sulfate (PS) is a polycationic protein drug obtained from the sperm of
fish, and is used to reverse the anticoagulant effect of unfractionated heparin (UFH). However,
the interactions between PS, UFH, and platelets are still not clear. We measured the platelet numbers
and collagen-induced aggregation, P-selectin, platelet factor 4, β-thromboglobulin, prostacyclin
metabolite, D-dimers, activated partial thromboplastin time, prothrombin time, anti-factor Xa,
fibrinogen, thrombus weight and megakaryocytopoiesis in blood collected from mice and rats
in different time points.. All of the groups were treated intravenously with vehicle, UFH,
PS, or UFH with PS. We found a short-term antiplatelet activity of PS in mice and rats, and
long-term platelet-independent antithrombotic activity in rats with electrically-induced thrombosis.
The antiplatelet and antithrombotic potential of PS may contribute to bleeding risk in PS-overdosed
patients. The inhibitory effect of PS on the platelets was attenuated by UFH without inducing
thrombocytopenia. Treatment with UFH and PS did not affect the formation, number, or activation of
platelets, or the thrombosis development in rodents.
Keywords: animal models; heparin; platelets; protamine; thrombocytopenia; thrombosis
1. Introduction
Protamine sulfate (PS), an alkaline protein consisting mainly of arginine, stabilizes DNA during
spermatogenesis. PS is used in medicine to reverse the anticoagulant activity of anionic unfractionated
heparin (UFH), and to stabilize neutral protamine Hagedorn (NPH) insulin [1]. Commercially available
PS is currently derived from the sperm nuclei of chum salmon fish, which were traditionally caught
at the north-eastern coast of the Japanese island of Honshu. The salmon fishing areas were moved
north of the Hokkaido island after the Japan earthquake and tsunami of 2011. The differences among
the individual fish acquired from the separate geographical populations resulted in a heterogeneity
of PS and its action. PS also may induce an anaphylactic reaction in patients receiving NPH insulin
or those with a fish allergy, which is probably related to its animal origin. Despite the above, PS is
still in use as it is a life-saving drug [1]. The postoperative PS infusion minimizes bleeding after UFH
administration [2]. However, the risk still exists and may increase by both the release of UFH from
complexes with PS [3], or with the additional doses of PS [4].
The anticoagulant properties of PS are related to its interaction with platelets, coagulation factors,
and fibrinolysis [5]. Under physiological conditions, platelets freely circulate in the blood vessels, and
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they are protected from activation by the healthy endothelium and its mediators, such as nitric oxide
(NO) and prostacyclin. The activation of platelets is a crucial step in arterial thrombosis development.
Adhesive glycoprotein receptors Ib/IX, Ia/IIa, VI, and IIb/IIIa interact with von Willebrand factor (vWF)
and collagen, among others, which capture the platelets and induce activation signals. The activated
platelets secrete agonists from dense- and α-granules, such as adenosine diphosphate, platelet factor 4
(PF4), or β-thromboglobulin (βTG), leading to further activation. Platelets serve as attachment sites
for coagulation factors, and as a source of those factors and other molecules, such as polyphosphates
(PolyP) and prothrombin. The initiated coagulation cascade and aggregated platelets contribute to
fibrin formation, which stabilizes the thrombus [6]. Direct exposure to PS may reduce the platelet
activity and aggregation, and induce thrombocytopenia. Transient thrombocytopenia (5–60 min)
was reported during UFH neutralization in female Sprague-Dawley rats [7], dogs [8], goats [9], and
humans [10]. Previous in-vitro studies have suggested that PS may adhere to the negatively charged
platelet membrane, and thus even induce platelet aggregation by forming bridges between adjacent
platelets, leading to thrombocytopenia [11]. It also interferes with glycoprotein Ib (GPIb) [12], which
plays a critical role in mediating platelet clearance [13]. PS complexed with UFH could alter the
platelet behavior and form complexes with them, which accumulate in the pulmonary and hepatic
circulation [7–10,14–19]. Some authors postulated that UFH and PS change blood cells through the
classical pathway of complement activation, which may result in transient thrombocytopenia [20].
There are many studies with often contradictory results on the short-term antiplatelet action of PS,
but there is a lack of information on the potential long-term platelets’ response. The clinical observation
is scarce and can hardly be attributed to PS.
Recently, it was proposed that multimolecular complexes of UFH and PS may induce the
production of platelet-activating immunoglobulin G (IgG) antibodies, which are responsible for severe
thrombocytopenia and thromboembolic complications [21–25]. This phenomenon has been observed in
the post-operative period, and more frequently in immunized patients with NPH insulin [21–24,26,27].
The Fc domains of the IgG antibody within the immune PS and UFH complex may bind to the platelet
Fcγ receptor type IIa, and activate platelets, leading to their aggregation and clearance, but other
Fc-independent mechanisms could also be taken into account [12,21,28,29]. However, a significant part
of the current data was obtained from patients taking more than one drug and undergoing invasive
cardiovascular procedures, which can mask the real effects of PS. The discrepancies may also be related
to the different times of platelet responses or the presence of antibodies.
The gaps in the potential hemostatic complications related to UFH neutralization by PS, and the
unclear platelet response to PS encouraged us to explore, in more detail, the interaction of UFH and PS
with platelets and thrombosis, with the use of relevant animal in-vivo models in a time-dependent
manner. In the present study, we investigated the number of platelets and the various markers of
platelet activation in mice and rats from three minutes up until five weeks, from single or repeated
injections of PS alone, or PS together with UHF. We also estimated the thrombopoiesis, as well as the
mechanisms involved in the thrombotic and hemorrhagic complications of drugs.
2. Results
2.1. The Effect of UFH and PS on the Number of Platelets and Their Function in Mice and Rats
We decided to choose a therapeutic dose of UFH (150 U/kg) that extended the activated partial
thromboplastin time (aPTT) by almost three times and the bleeding time by half in rats [30]. The PS
dose was determined based on the clinical practice, finding that 1 mg of PS neutralizes 100 U of UFH.
PS alone slightly decreased the platelet count at 15 min in the mice, while we observed a similar
but even smaller decrease in the platelet count in a group treated with UFH and PS. The number of
platelets returned to a normal level at the 60 min in both groups (Figure 1a).
There was no statistical difference in platelet count in the mice treated once a week with UFH and
PS, or PS alone for 35 days, but we noted a drop in the number of platelets, to below 50%, in three out
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of the seven mice treated with UFH and PS at the end of the experiment (Figure 1a). In the rats, we did
not observe any changes in the platelet count during the whole experiment (Figure 1b).
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Figure 1. Platelet number in (a) mice (n = 5–8) and (b) rats (n = 5–10) at 3, 15, 30, and 60 minutes, and 
on the 35th day after the administration of unfractionated heparin (UFH) and protamine sulfate (PS). 
The results are expressed as a percentage of the control samples, and are shown as a median (line) 
with the interquartile range (box), and maximum and minimum values (whiskers). The number of 
platelets in the vehicle-treated groups was 617 (565–675) at 3 and 15 minutes, 705 (670–752) at 60 
minutes, and 427 (326–467) on the 35th day in the mice. In the rats, the control values were 446 (176–
754), 725 (372–746), 668 (196–781), and 637 (494–660) at 15, 30, and 60 minutes, and on the 35th day, 
respectively. *p < 0.05; **p < 0.01 vs vehicle group; Kruskal–Wallis analysis of variance (ANOVA) with 
Dunn’s post-hoc test. 
 
Figure 2. Platelet aggregation results in mice at 3, 15, and 60 minutes (n = 4–7), and on the 35th day (n 
= 5–7) after unfractionated heparin (UFH) and protamine sulfate (PS) administration. (a) Collagen-
induced platelet aggregation expressed as the maximal extension (MaxA), (b) the slope of platelet 
aggregation (Slp), (c) lag time, and (d) the area under the curve (AUC). The results are expressed as a 
percentage of the control samples, and are shown as the median (line) with the interquartile range 
(box), and maximum and minimum values (whiskers). The control values at 3 and 15 minutes were 
11.0 (10.0–13.0), 9.0 (6.0–10.0), 115.0 (104.0–174.0), and 31.3 (21.1–40.4); at 60 minutes they were 10.5 
(10.0–11.0), 4.0 (4.0–5.0), 137.0 (112.0–151.0), and 25.5 (21.4–30.6); and on the 35th day, they were 6.0 
(4.0–8.0), 3.0 (3.0–4.0), 190.0 (150.0–270.0), and 11.6 (3.8–15.7), for MaxA, Slp, lag time, and AUC, 
Figure 1. Platelet number in (a) mice (n = 5–8) and (b) rats (n = 5–10) at 3, 15, 30, and 60 minutes, and
on the 35th day after the administration of unfractionated heparin (UFH) and protamine sulfate (PS).
The results are expressed as a percentage of the control samples, and are shown as a median (line) with
the interquartile range (box), and maximum and minimum values (whiskers). The number of platelets
in the vehicle-treated groups was 617 (565–675) at 3 and 15 minutes, 705 (670–752) at 60 minutes, and 427
(326–467) on the 35th day in the mice. In the rats, the control values were 446 (176–754), 725 (372–746),
668 (196–781), and 637 (494–660) at 15, 30, and 60 minutes, and on the 35th day, respectively. * p < 0.05;
** p < 0.01 vs. vehicle group; Kruskal–Wallis analysis of variance (ANOVA) with Dunn’s post-hoc test.
PS administered alone significantly inhibited the platelet aggregation in the mice at 15 and
60 min (Figure 2), and in the rats at 60 min (Figure 3). UFH attenuated the inhibitory effect of PS on
the platelets (Figure 2). The UFH and PS treatment only slightly delayed collagen-induced platelet
aggregation 15 min after a single injection into the mice (Figure 2). We observed no changes in the
platelet aggregation after 35 days in the mice (Figure 2) and rats (Figure 3).
Mar. Drugs 2019, 17, x FOR PEER REVIEW 3 of 18 
 
Figure 1. Platelet number in (a) mice (n = 5–8) and (b) rats (n = 5–10) at 3, 15, 30, and 60 minutes, and 
on the 35th day after the administration of unfractionated heparin (UFH) and protamine sulfate (PS). 
The results are expressed as a percentage of the control samples, and are shown as a median (line) 
with the interquartile range (box), and maximum and minimum values (whiskers). The number of 
platelets in the vehicle-treated groups was 617 (565–675) at 3 and 15 minutes, 705 (670–752) at 60 
minutes, and 427 (326–467) on the 35th day in the mice. In the rats, the control values were 446 (176–
754), 725 (372–746), 668 (196–781), and 637 (494–660) at 15, 30, and 60 minutes, and on the 35th day, 
respectively. *p < 0.05; **p < 0.01 vs vehicle group; Kruskal–Wallis analysis of variance (ANOVA) with 
Dunn’s post-hoc test. 
 
Figure 2. Platelet aggregation results in mice at 3, 15, and 60 minutes (n = 4–7), and on the 35th day (n 
= 5–7) after unfractionated heparin (UFH) and protamine sulfate (PS) administration. (a) Collagen-
induced platelet aggregation expressed as the maximal extension (MaxA), (b) the slope of platelet 
aggregation (Slp), (c) lag time, and (d) the area under the curve (AUC). The results are expressed as a 
percentage of the control samples, and are shown as the median (line) with the interquartile range 
(box), and maximum and minimum values (whiskers). The control values at 3 and 15 minutes were 
11.0 (10.0–13.0), 9.0 (6.0–10.0), 115.0 (104.0–174.0), and 31.3 (21.1–40.4); at 60 minutes they were 10.5 
(10.0–11.0), 4.0 (4.0–5.0), 137.0 (112.0–151.0), and 25.5 (21.4–30.6); and on the 35th day, they were 6.0 
(4.0–8.0), 3.0 (3.0–4.0), 190.0 (150.0–270.0), and 11.6 (3.8–15.7), for MaxA, Slp, lag time, and AUC, 
Figure 2. Platelet aggregation results in mice at 3, 15, and 60 minutes (n = 4–7), and on the 35th day (n =
5–7) after unfractionated heparin (UFH) and protamine sulfate (PS) administration. (a) Collagen-in uced
platelet aggregation expr ssed as the maxim l extension (MaxA), (b) the slope of platelet ggreg tio
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(Slp), (c) lag time, and (d) the area under the curve (AUC). The results are expressed as a percentage
of the control samples, and are shown as the median (line) with the interquartile range (box), and
maximum and minimum values (whiskers). The control values at 3 and 15 minutes were 11.0 (10.0–13.0),
9.0 (6.0–10.0), 115.0 (104.0–174.0), and 31.3 (21.1–40.4); at 60 minutes they were 10.5 (10.0–11.0), 4.0
(4.0–5.0), 137.0 (112.0–151.0), and 25.5 (21.4–30.6); and on the 35th day, they were 6.0 (4.0–8.0), 3.0
(3.0–4.0), 190.0 (150.0–270.0), and 11.6 (3.8–15.7), for MaxA, Slp, lag time, and AUC, respectively. * p <
0.05; ** p < 0.01 vs. vehicle; ˆ p < 0.05; ˆˆ p < 0.01 vs. PS group; Kruskal–Wallis ANOVA with Dunn’s
post-hoc test.
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Figure 3. Platelet aggregation results in rats at 60 min (n = 5–7) and on the 35th day (n = 9–10) after
unfractionated heparin (UFH) and protamine sulfate (PS) administration. (a) Collagen-induced platelet
aggregation expressed as the maximal extension (MaxA), (b) the slope of platelet aggregation (Slp),
(c) lag time, and (d) area under the curve (AUC). The results are expressed as a percentage of the
control samples and are shown as the median (line) with the interquartile range (box), and maximum
and minimum values (whiskers). The control values at 60 min were 8.5 (6.0–10.5), 4.0 (3.0–4.5), 156.0
(102.5–199.0), and 20.7 (9.7–25.2), and on the 35th day were 7.0 (3.5–9.0), 4.0 (2.0–5.0), 133.5 (85.0–220.0),
and 17.4 (5.4–27.3) for MaxA, Slp, lag time, and AUC, respectively. * p < 0.05 vs. vehicle group;
Kruskal–Wallis ANOVA with Dunn’s post-hoc test.
We observed a significant reduction in the P-selectin concentration (Figure 4a), and no changes in
the PF4 (Figure 4b) and βTG concentration (Figure 4c) in the mice treated repeatedly (once a week)
with UFH alone, or together with PS, for 35 days.
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Figure 4. Effects of unfractionated heparin (UFH) and protamine sulfate (PS) on (a) P-selectin, (b)
platelet factor 4 (PF4), and (c) β-thromboglobulin (βTG) concentration in mice (n = 6–8) on the 35th day
of the experiment. The results are shown as the median (line) with the interquartile range (box), and
maximum and minimum values (whiskers). * p < 0.05; ** p < 0.01 vs. vehicle group; Kruskal–Wallis
ANOVA with Dunn’s post-hoc test. VEH—vehicle.
2.2. The Effect of UFH and PS on Thrombosis and Coagulation Parameters in Mice and Rats
There was no change in the aPTT (Figure 5a) and D-dimer (Figure 5b) concentration in the
mice. The PS significantly decreased the thrombus weight after repeated intravenous administration
in the rats developing arterial thrombosis (0.86 (0.63–1.24) vs. 1.11 (0.66–1.35) mg in the vehicle
group, Figure 5c). The UFH administered together with PS slightly prolonged the prothrombin time
(PT; Figure 5d) in the rats on the 35th day of the experiment. There was no change in the aPTT
(Figure 5e), D-dimer (Figure 5f) concentration, fibrinogen (Figure 5g) concentration, anti-factor Xa
(anti-fXa, Figure 5h) activity, and 6-keto PGF1α (Figure 5i) concentration in the rats. In general, except
for the thrombus weight, all of the significant changes in the coagulation parameters did not exceed 5%.
2.3. The Effect of UFH and PS on Megakaryocytopoiesis in Mice
The thrombopoietin (TPO) levels decreased in the mice treated with UFH alone, or with UFH
with PS, after five weeks, compared with the levels measured one week after the first injection; but
no changes were observed in comparison to the vehicle-treated group (Figure 6). The analysis of the
hematopoietic composition of the bone marrow showed a similar percentage of megakaryocytes in
each preparation from the mice treated repeatedly with UFH and PS alone or together (Figure 7a).
No morphological differences in any of the bone marrow cells were observed between the control
and test groups (Figure 7a,b). The median counts of the total red and white blood cells, monocytes,
and lymphocytes are shown in Table S1. We reported significant differences between the vehicle and PS
groups with regard to the percentage of polychromatic erythroblasts, and the total erythroid cells (E) to
total myeloid cells (M) ratio (M/E). The mice repeatedly exposed to UFH and PS showed a significantly
lower percentage of basophilic erythroblasts, without affecting the M/E ratio. We observed a relatively
high percentage of metamyelocytes in the UFH and PS treated group, which could be attributed to PS
itself. The mice in the UFH group showed a reduced percentage of promyelocytes and lymphocytes,
of which the latter cell category was found to be significantly lower in the group treated with UFH and
PS. We did not find the platelet clusters in any of the preparations, but all of them had damaged cells
and fibers as a result of the smear technique.
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Figure 5. Effects of unfractionated heparin (UFH) and protamine sulfate (PS) on the (a) activated partial
thromboplastin time (aPTT) and (b) D-dimer concentration in mice (n = 3–7), and (c) thrombus weight,
(d) prothrombin time (PT), (e) activated partial thromboplastin time (aPTT), (f) D-dimer concentration,
(g) fibrinogen concentration, (h) anti-factor Xa (anti-fXa) activity, and (i) 6-keto PGF1α concentration
in rats (n = 9–10) on the 35th day of the experiment. The results are shown as the median (line) with
the interquartile range (box), and maximum and minimum values (whiskers). * p < 0.05; ** p < 0.01;
Kruskal–Wallis ANOVA with Dunn’s post-hoc test.
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Figure 7. The morphology of megakaryocytes (MK), and their number per 100-cell count for bone 
marrow (%), shown as the median with range. (a) The arrows in the top panel indicate MK, and (b) 
the bottom panel represent the remaining bone marrow cell lines at a 1000-fold magnification in bone 
marrow smears from mice (n = 8) treated repeatedly with unfractionated heparin (UFH) and 
protamine sulfate (PS). May–Grünwald–Giemsa stain (Merck) following the standard protocol. 
Microscope: Olympus CH 30; objectives: DPlanC 100, 1.25 oil, 160/0.17; DPlanC 40, 0.65, 160/0.17; 
camera: Digital Sight DS.-Fi1 Nikon. 
2.4. The Effect of UFH and PS on the Blood Count in the Mice and Rats 
UFH and PS mainly changed the parameters characterizing the red blood cells shortly after 
concomitant administration into both rodents. However, the decrease in the red blood cell number, 
hemoglobin level, haematocrit, mean corpuscular haemoglobin, and mean corpuscular haemoglobin 
Figure 6. The thrombopoietin level (TPO) during the repeated administration of unfractionated heparin
(UFH) and protamine sulfate (PS) in mice (n = 6–8). The serum TPO concentration was measured by
specific enzyme-linked immunosorbent assay (ELISA). The results are shown as the median (line) with
the interquartile range (box), and maximum and minimum values (whiskers). * p < 0.05 vs. the first
week within the same group; Friedman ANOVA with Dunn’s post-hoc test.
Mar. Drugs 2019, 17, x FOR PEER REVIEW 7 of 18 
 
Figure 6. The thrombopoietin level (TPO) during the repeated administration of unfractionated 
heparin (UFH) and protamine sulfate (PS) i  mice (n = 6–8). The serum TPO conce tration was 
measured by specific enzyme-linked immunosorbent as ay (ELISA). The results are hown as the 
median (line) with th  interq artile ra ge (box), and maximum and minimum values (whiskers). *p < 
0.05 vs the first week within the sa e gro p; Fried an ANOVA with Dunn’  post-hoc test. 
 
Figure 7. The morphology of megakaryocytes (MK), and their number per 100-cell count for bone 
marrow (%), shown as the median with range. (a) The arrows in the top panel indicate MK, and (b) 
the bottom panel represent the remaining bone marrow cell lines at a 1000-fold magnification in bone 
marrow smears from mice (n = 8) treated repeatedly with unfractionated heparin (UFH) and 
protamine sulfate (PS). May–Grünwald–Giemsa stain (Merck) following the standard protocol. 
Microscope: Olympus CH 30; objectives: DPlanC 100, 1.25 oil, 160/0.17; DPlanC 40, 0.65, 160/0.17; 
camera: Digital Sight DS.-Fi1 Nikon. 
2.4. The Effect of UFH and PS on the Blood Count in the Mice and Rats 
UFH and PS mainly changed the parameters characterizing the red blood cells shortly after 
concomitant administration into both rodents. However, the decrease in the red blood cell number, 
hemoglobin level, haematocrit, mean corpuscular haemoglobin, and mean corpuscular haemoglobin 
Figure 7. The morphology of megakaryocytes (MK), and their number per 100-cell count for bone
marrow (%), shown as the median with range. (a) The arrows in the top panel indicate MK, and (b)
the bottom panel represent the remaining bone marrow cell lines at a 1000-fold magnification in bone
marrow smears from mice (n = 8) treated repeatedly with unfractionated heparin (UFH) and protamine
sulfate (PS). May–Grünwald–Giemsa stain (Merck) following the standard protocol. Microscope:
Olympus CH 30; objectives: DPlanC 100, 1.25 oil, 160/0.17; DPlanC 40, 0.65, 160/0.17; camera: Digital
Sight DS.-Fi1 Nikon.
2.4. The Effect of UFH and PS on the Blood Count in the Mice and Rats
UFH and PS mainly changed the parameters characterizing the red blood cells shortly after
concomitant administr tion i to both r ents. However, he ecrease in the re blood cell number,
hemoglobin level, haematocrit, mean c rpuscular haemoglobin, and mean corpuscular haemoglobin
concentration, and the increase in the mean orpuscular volume were slight and in the nor al range
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(below 8% in comparison to control group). PS alone significantly decreased the number of erythrocytes,
the hemoglobin level, and hematocrit in the rats (Table S2), but not in the mice (Table S3), 60 min
after injection. UFH alone reduced the number of red blood cells, while increasing their mean volume
after 3 min in the mice (Table S3). Other than a 3.9% decrease in the mean corpuscular haemoglobin
concentration after the repeated administration of UFH, and a 5.5% decrease in the haemoglobin level
after the repeated administration of UFH with PS, we observed no changes in the blood count on day
35 of the experiment, in comparison to the vehicle-treated mice and rats (Tables S2 and S3).
3. Discussion
In our present study, we focused on the marine-origin drug, protamine sulfate, and its hemostatic
complications during UFH neutralization, which presents an unresolved problem, with contradictory
results published so far. We studied the effects of PS alone, or together with UFH, on the number of
platelets and their function in rodents, from 3 min to 35 days after the drug administration. We also
investigated the mechanisms of this interaction by measuring the activation markers of the platelets
and coagulation, as well as the involvement of the megakaryocytopoiesis. We found an inhibitory
effect of PS on platelet aggregation without inducing thrombocytopenia, which was attenuated by the
concomitant administration of UFH in the mice. When injected once a week for five weeks, PS slightly
inhibited the arterial thrombosis development in rats, without changing the platelet activity or their
number, the clotting times, and the D-dimers levels in both rodents. The PS administered together
with UFH in the therapeutic doses into the mice and rats did not induce significant thrombocytopenia,
the activation of platelets, arterial thrombosis development and abnormalities in megakaryocytopoiesis,
or platelet formation.
We observed previously that PS slightly decreased the thrombus weight and platelet aggregation,
and increased the tail bleeding time without changing the aPTT in rats during a 1-h experiment [30].
In the present study, PS inhibited the collagen-induced platelet aggregation. However, the effect
appeared 15 min after administration, and lasted for 1 h. It seems that the antithrombotic effect
is species-independent, because it occurred not only in the mice, but also in the rats. We did not
observe any significant changes in the platelet numbers in the mice and rats treated with PS alone
or with UFH, except for a slight trend to decrease at 15 min. Generally, in the studies reporting
thrombocytopenia, the doses of PS were higher compared with our experiment. This effect could
depend on the doses and ratio, strain, sex, or species. The mechanism underlying the antiplatelet effect
of PS is multifactorial, and may include the inhibition of platelet aggregation [4,31], sensitivity [32],
GPIb–vWF activity [12], P-selectin expression [33], thrombin generation [34], and the release of
intracellularly stored adenosine diphosphate and PF4 [35]. However, most evidence comes from
in vitro studies, which did not take into account the involvement of the endothelial response [5]. In one
of the studies, PS inhibited the collagen-induced activation of the platelets exposed to shear stress [36].
PS consists of L-arginine, which is the physiological precursor of strong antiplatelet agent, NO, with an
extremely short half-life [37]. The release of L-arginine into circulation could play a primary role in
the antiplatelet effect. The polycationic structure of PS and its nonspecific interactions with various
hemostatic elements can enhance this activity, especially considering that we observed no effect when
PS was complexed with UFH. Possibly by the electrostatic binding of GPIb, PS impairs the GPIb–vWF
activity and the adhesion of platelets to collagen. The GPIb–vWF interaction is mandatory for normal
hemostasis, and its impairment leads to a reduced platelet aggregation and risk of bleeding [12].
Interestingly, it seems that UFH, a typical anticoagulant drug, attenuated the inhibitory effect of PS
on platelets. Despotis et al. reported that lower doses of PS in relation to the UFH dose reduced the
blood consumption, as a result of the better preservation of the coagulation system, including platelet
function [38]. The mechanism by which UFH attenuates the inhibitory effect of PS on platelets may be
the same as the mechanism by which PS is the antidote for the UFH anticoagulant effect. We have
previously clearly shown that PS binds 100% of UFH, which reverses at least the anticoagulant effect of
UFH [39]. There are also studies confirming that the well-known pulmonary toxicity of PS is weakened
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by UFH. The polycations damage the pulmonary vascular beds by the neutralization of the anionic
endothelial surface, which leads to an increased vascular permeability. The negatively-charged UFH
binds and removes the circulating PS from the bloodstream, or it is possible that UFH counters the effect
of the positively-charged PS molecules [40–42]. Perhaps UFH could be therapeutic in some cases of
life-threatening PS reactions, and the administration of UFH first should be considered. The data from
patients after cardiopulmonary bypass (CPB) indicated that UFH dose-based PS administration resulted
in its overdose and in the impairment of the coagulation system [43]. An approximately 1.4:1 PS to
UFH ratio significantly prolonged the clotting time in the thromboelastometry [43]. PS management
based on the UFH concentration avoids haemorrhagic complications after cardiac surgery when
compared with the conventional approach [43,44]. In general, the PS dose to UFH should not exceed
1:1, in order to avoid bleeding complications. The serious cardiovascular side effects of PS led to a
search for alternative replacers. Universal heparin reversal agents (UHRA), low molecular weight
protamine, Dex40-GTMAC3, and heparin binding copolymers are all in the preclinical stage; aripazine
is already in the clinical phase, whereas andexanet alfa is registered for the reversal of oral direct Xa
inhibitors [37,45–48].
Recently, it was suggested that the long-term response of platelets to UFH and PS complexes
can be different, especially in patients who have had contact with PS in the past. The administration
of UFH and PS induces the formation of platelet-reactive anti-UFH/PS antibodies, which could be
responsible for the increased risk of severe thrombocytopenia and thromboembolic complications in
the postoperative period, especially after CPB [21,24,25]. We wanted to simulate this clinical scenario
so as to study the long-term response of platelets to PS, or PS and UFH complexes. We previously
found IgG antibodies in the blood of mice three weeks after the first injection of UFH and PS, achieving
a maximal concentration in week five [39]. Therefore, we repeatedly administered, once a week for five
weeks, PS or PS with UFH. In our experimental setting, all of the animals survived until day 35, and did
not show any symptoms of thrombosis, and platelets activation. We did not observe any changes in the
concentrations of platelet activation markers, βTG, PF4, and soluble P-selectin, for which raised levels
may predict adverse cardiovascular events [49]. We found a decrease in the concentration of P-selectin
in the mice treated with UFH and PS. As an even greater decrease was observed in the group treated
with UFH alone, it could be as a result of PS-binding by UFH, which serves as a ligand for P-selectin [50].
We did not observe any changes in D-dimer concentration in the 35th day. The median platelet count
did not significantly decrease in the animals exposed to UFH and PS, but in three out of the seven mice,
the platelet count decreased by half. The prolonged immune-mediated thrombocytopenia may not
result from the platelet depletion, but from their impaired formation [51,52]. Bakchoul et al. provided
evidence that anti-UFH/PS antibodies can affect megakaryocytopoiesis in the presence of UFH and
PS [22]. In our study, the UFH and PS group did not show marked signs of megakaryocyte disruption
compared to the control group. The percentage of other bone marrow cells changed in the mice treated
with PS together with UFH. However, the bone marrow morphology may reflect changes resulting
from decreased body weight gain [53]. Also, we did not observe abnormalities in the thrombopoiesis.
The TPO production was sufficient to induce the formation of new platelets in all of the groups for five
weeks. We noticed a slight decrease in the TPO concentration in week five in the UFH alone, and in
the UFH and PS treated group, compared to the first measurement. This effect and the prolonged PT
might be indicators of liver damage, as we previously found cellular changes in the mice livers after
the injection of UFH and PS [54,55].
In summary, we did not confirm that the PS or UFH and PS treatments carry a long-term risk of
platelet activation and thrombocytopenia, at least in the mice. We repeated the same experiment in
rats, as there were previously reported species differences in the platelets’ response to UFH and PS.
We additionally electrically induced arterial thrombosis in the rats at the end of the experiment so as to
study the long-term effect of PS on thrombosis development. A rat model also allowed us to collect
more blood for measuring the coagulation markers in order to study the potential mechanisms of the
anticoagulant effects of PS. Similar to the mice, we did not observe changes in the platelet number and
Mar. Drugs 2019, 17, 539 10 of 18
platelets aggregation five weeks after the repeated administration of PS and UFH, and no effect on
thrombosis. We only noticed about a 5% change of PT in the UFH and PS group. A trend toward an
increase of PT in the UFH-treated rats suggests that UFH by itself could contribute to PT prolongation.
There are reports that PS prolongs PT by the inhibition of the activity of factors V, VII, and X [56]. Thus,
it also could be an additive effect of both drugs. A very low thrombosis ratio (2/591) was also noted
in the patients reversed with PS during CPB [25], so it is possible we could not detect such a rare
effect in normal animals. The platelet count or its recovery is impaired by hemorrhagic conditions or
contact with artificial surfaces, a common situation during CPB in humans. The platelet responses
may also depend on the different progression of cardiovascular disease or complex pharmacotherapy.
The anatomy/physiology differences between rodents and humans could also be a reason, especially if
we take into account the complex nature of the immune and hemostasis systems. In our animal study,
we eliminated platelet-modifying factors so as to solely study the effect of UFH and PS. Perhaps the
UFH and PS treatment can only slightly enhance the effect of other factors on the platelets during CPB.
Interestingly, the repeated administration of PS slightly, but significantly, inhibited thrombosis,
without any changes in the platelet aggregation and coagulation tests. Perhaps the once a week
administration of short-acting PS inhibits the platelets temporarily and reversibly. Based on our
results, we can rather exclude the mechanisms involving clotting factors or platelets as the primary
reason for the long-term antithrombotic effect of PS. The results of other studies suggest that the
enhancement of fibrinolysis could contribute to the long-term antithrombotic effect of PS. The thrombin
generation in murine and human plasma was significantly reduced by PS in a dose-dependent
manner [56,57]. However, Ni Ainle et al. suggested that thrombin inhibition plays only a minor
role in the PS anticoagulation effect [56]. PS significantly decreased the clot strength and enhanced
fibrinolysis, which might occur through several possible mechanisms [58]. The down-regulation of
thrombin generation decreases the activation of the thrombin-activatable fibrinolysis inhibitor [56,57].
Furthermore, PS inhibits both the tissue factor-dependent and direct thrombin generation, and then
fibrinogen polymerization and the cross-linking of fibrin [58]. In the turbidimetric assays performed
by Kalathottukaren et al., PS increased the clot turbidity. According to the authors, this phenomenon
may result from the nonenzymatic polymerization or precipitation of fibrinogen, the incorporation of
PS into fibrinogen or fibrin, or by impairing thrombin generation. They showed that PS is incorporated
within the clot structure, which led to an abnormal clot architecture and enhancement fibrinolysis [46].
As mentioned before, the repeated releases of profibrinolytic and vasorelaxant NO by L-arginine
from PS could also play a role here [59]. The second important endothelial mediator able to exert an
antithrombotic activity is prostacyclin [60–62], but we found no changes in the plasma concentration
of prostacyclin metabolite, 6-keto-PGF1α, in the rats receiving PS. The antithrombotic activity of the
synthetic cationic macromolecules, such as UHRA, was explained by their binding to endogenous
polyanionic molecules, PolyP, with a prothrombotic activity [63]. PolyP, through the influence on the
coagulation cascade, enhances the thrombin generation. In addition, it incorporates into fibrin clots to
stabilize them [63]. Perhaps PS, as a natural cationic macromolecule, could also have a similar ability.
4. Materials and Methods
4.1. Materials
We used trisodium citrate (≥99%), dipotassium ethylenediaminetetraacetic acid (K2EDTA,
analytical grade), PS from salmon (grade X; Sigma-Aldrich, Darmstadt, Germany), UFH from bovine
intestinal mucosa (Polfa Warszawa, Warsaw, Poland), isoflurane (Baxter Polska, Warsaw, Poland),
pentobarbital, ketamine, xylazine (Biovet, Pulawy, Poland), phosphate buffered saline (Biomed Lublin,
Lublin, Poland), aPTT, PT and fibrinogen reagents (Bio-Ksel, Grudziadz, Poland), anti-factor Xa assay
kit (Sekisui Diagnostics, Burlington, MA, USA), mouse sP-selectin/CD62P, mouse thrombopoietin
(R&D Systems, Inc., Minneapolis, MN, USA), D-dimer, PF4, βTG (Cloud-clone corp., Katy, TX, USA),
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and 6-keto-PGF1α ELISA kits (Cayman Chemicals, Ann Arbor, MI, USA), and collagen (Chrono-log,
Havertown, PA, USA).
4.2. Animals and Housing
The animals were obtained from the Centre of Experimental Medicine at the Medical University
of Bialystok. The animals were bred in a 12-hour light/dark cycle, in a temperature- and
humidity-controlled room, and were allowed to have ad-libitum access to sterilized water and
standard chow in specific pathogen-free conditions. All of the procedures involving animals were
approved by the Local Ethical Committee on Animal Testing (permits: 92/2012, 108/2015, 2/2018, and
60/2018), and were conducted by Directive 2010/63/EU of the European Parliament and the Council on
the Protection of Animals, the ARRIVE guidelines, and the national laws. The animals were euthanized
by exsanguination at the end of the experiments.
4.3. Experiment 1: The Number of Platelets and Their Aggregation up to 60 Min after A Single Injection of
UFH and PS into Mice
The blood samples were collected from the hearts each of 71 male BALB/c mice (21.1 ± 2.4 g),
at five weeks old, after being anesthetized with a mixture of isoflurane and medical air (1.5–3% v/v),
and were drawn into 3.13% trisodium citrate in a volume ratio of 9:1 at the end of the experiment.
The blood cells were counted 3, 15, and 60 min following injection into the right femoral vein of the
vehicle (phosphate buffered saline, 1 mL/kg), UFH (150 U/kg, 1 mL/kg), PS (1.5 mg/kg, 1 mL/kg), or
both (Figure 8a), using the Animal Blood Counter (ABC Vet, Horiba ABX Sp. z o.o., Warsaw, Poland).
At the same time, the points platelet aggregation was measured after the incubation of the whole blood
(500 µL) and 0.9% NaCl solution (500 µL) for 20 min at 25 ◦C, and then for 15 min at 37 ◦C. The changes
in impedance were registered for 6 min after the collagen addition (5 µg/mL) using a Chrono-log
aggregometer (Chrono-log Corp., Havertown, PA, USA). The aggregation curve was described by the
maximal extension, the slope of the platelet aggregation, lag phase, and the area under the curve.
4.4. Experiment 2: The Number of Platelets and Their Aggregation, Bone Marrow Cytology, and Coagulation
Parameters 35 Days after the Repeated (Once a Week) Injection of UFH and PS into Mice
PS (1.5 mg/kg, 1 mL/kg) and UFH (150 U/kg, 1 mL/kg) alone or in combination were injected
once weekly into the tail veins of 32 male BALB/c mice (26.0 ± 1.7 g), eight weeks old, during five
weeks. The vehicle-treated (phosphate buffered saline, 1 mL/kg) animals served as a control group.
The blood was collected four times from each animal, anesthetized with a mixture of isoflurane and
medical air (3% v/v) by puncture of the retro-orbital plexus on the day before the drug administration
(Figure 8a). The blood samples were centrifuged at 8000 rpm at 22 ◦C for 5 min after 1-h of incubation
at room temperature, and the serum was deep-frozen (−80 ◦C) until the further determination of TPO
concentration by immunoassay (R&D Systems, Minneapolis, MN, USA). No deaths, drug-related
clinical signs of toxicity, effects on food consumption, or visual changes were reported during the 35-day
observation. We did not observe significant differences in the mean baseline body weights between the
treatment groups. The mean body weight did not increase equally in all of the groups. We only noted
a slight, but significant, decrease in body weight gain in the mice treated with PS and with UFH and
PS in the second and fifth week of the experiment, respectively (Figure 8b). Blood was collected from
the hearts under anesthesia (a mixture of isoflurane and medical air; 3% v/v) one week after the last
drug dose administration. The platelet aggregation and blood cell count were measured according to
the methods described above, with the collagen addition at a concentration of 5 µg/mL. The serum was
separated and used for the determination of TPO, P-selectin (R&D Systems, Minneapolis, MN, USA),
PF4, and the βTG concentration (Cloud-Clone Corp., Katy, TX, USA) in a microplate reader (Synergy
HTX, BioTek, Winooski, VT, USA), according to the kit manufacturer’s directions. Sodium citrate
anticoagulated blood samples were centrifuged at 3500× g at 4 ◦C for 10 min, and the plasma was
deep-frozen (−80 ◦C) until further assays could be performed. The aPTT was automatically determined
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by an optical method (Coag Chrom 4000, Bio-Ksel, Grudziadz, Poland), adding routine laboratory
reagents (Bio-Ksel, Grudziadz, Poland). The plasma concentration of D-dimer was measured by the
ELISA technique, using a microplate reader (Synergy HTX, BioTek, Winooski, VT, USA) to monitor
the changes in absorbance according to the kit manufacturer directions (Cloud-Clone Corp., Katy, TX,
USA). Following the blood collection, the animals were euthanized, and the bone marrow from the
femurs were collected immediately for cytological examination. The bone marrow smears were stained
by the May–Grünwald–Giemsa method. The morphology was assessed by examination with a ×40
objective, and a 100-cell count for the bone marrow was performed with a ×100 objective. Any cell that
did not fit the definition was counted with the category it most closely resembled.
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Figure 8. Schematic representation of (a) the study protocol, and (b) the mean body weight gain
expressed as a percentage of the body weight before treatment with unfractionated heparin (UFH) and
protamine sulfate (PS) in mice (n = 8) during the second experiment. The results are shown as mean ±
standard deviation (SD).* p < 0.05 vs. vehicle, ANOVA with Fisher’s LSD post hoc test.
4.5. Experiment 3: The Number of Platelets and Their Aggregation up to 60 Min after a Single Injection of UFH
and PS into Rats
The blood samples were collected from the tail arteries of 32 male Wistar rats (177.7 ± 13.5 g), at
seven weeks old, after being anesthetized by an intraperitoneal injection of pentobarbital (45 mg/kg),
using K2EDTA as an anticoagulant. The blood cells were counted 15, 30, and 60 min following injection
into the right femoral vein of the vehicle (phosphate buffered saline, 1 mL/kg), UFH (150 U/kg, 1 mL/kg),
PS (1.5 mg/kg, 1 mL/kg), or both (Figure 9a), using the Animal Blood Counter (ABC Vet, Horiba ABX
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Sp. z o.o., Warsaw, Poland). The blood samples were collected from the heart and drawn into 3.13%
trisodium citrate in a volume ratio of 9:1 at the end of the experiment. The platelet aggregation was
measured according to the methods previously described, with the collagen addition at a concentration
of 7.5 µg/mL.
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Figure 9. Schematic representation of (a) the study protocol and (b) the mean body weight gain
expressed as a percentage of the body weight before treatment with unfractionated heparin (UFH) and
protamine sulfate (PS) in rats (n = 9–10) during the fourth experiment. The results are shown as mean
± SD. ANOVA with Fisher’s LSD post-hoc test.
4.6. Experiment 4: The Number of Platelets and Their Aggregation, Arterial Thrombosis, and Coagulation
Parameters 35 Days after the Repeated (Once a Week) Injection of UFH and PS into Rats
PS (1.5 mg/kg, 1 mL/kg) and UFH (150 U/kg, 1 mL/kg), alone or in combination, were injected
once a week into the tail veins of 38 male Wistar rats (130.5 ± 9.9 g), at five weeks old, after being
anesthetized with a mixture of isoflurane and medical air (3% v/v; Figure 9a). The vehicle-treated
(phosphate buffered saline, 1 mL/kg) animals served as a control group. No deaths, drug-related
clinical signs of toxicity, effects on food consumption, or visual changes were observed in the study.
We did not observe significant differences in the mean baseline body weights between the randomized
treatment groups. The mean body weight of the control rats increased from 129.0 ± 9.6 g at baseline,
to 283.6 ± 7.8 g during 35 days, and it was similar in the rats receiving drugs (Figure 9b). Arterial
thrombosis was induced by the electrical stimulation (1 mA/10 min) of the common carotid artery
during anesthesia with pentobarbital (45 mg/kg, i.p.), one week after the last drug administration, as
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described previously [30]. The formed thrombus was completely removed 45 min after thrombosis
induction, air-dried at 37 ◦C, and weighed 24 h after the end of the experiment. The blood cell count
and platelet aggregation were measured according to the methods described above, with the collagen
addition at a concentration of 7.5 µg/mL. The sodium citrate anticoagulated blood samples were
centrifuged at 3500× g at 4 ◦C for 20 min, and the plasma was deep-frozen (−80 ◦C) until further assays
could be performed. The aPTT, PT, and fibrinogen concentrationd were automatically determined
by an optical method (Coag Chrom 4000, Bio-Ksel, Grudziadz, Poland), adding routine laboratory
reagents. The plasma concentrations of 6-keto-PGF1α (Cayman Chemicals, Ann Arbor, MI, USA)
and D-dimer (Cloud-clone corp., Katy, TX, USA) were measured by the ELISA technique, using a
microplate reader (Synergy HTX, BioTek, Winooski, VT, USA) to monitor the changes in absorbance
according to the kit manufacturer directions.
4.7. Statistical Analysis
In the study, n refers to the number of animals in each experimental group. We chose a minimal
number of animals to detect the differences between each group based on our experience as well as
others’ experience using these procedures. The data are shown as the median, with the lower and
upper limits, or mean ± SD. All of the data sets were tested for normality with the Shapiro–Wilk test.
Multiple group comparisons were performed using the ANOVA with Dunn’s or Fisher’s LSD post-hoc
tests, depending on whether the data have a normal or non-normal distribution. The results were
analyzed and graphically presented using GraphPad Prism 8 (GraphPad Software, La Jolla, CA, USA).
P values < 0.05 were considered significant.
5. Conclusions
In summary, we showed a clear direct antiplatelet effect of PS in vivo, which was present 15–60 min
from PS administration, and absent when PS was administered once a week or together with UFH.
Interestingly, PS administered chronically inhibited arterial thrombosis in rats. However, it is impossible
to consider PS as an antithrombotic medicine, because of its serious adverse cardiovascular effects. PS
dosing is usually based on clinical experience rather than evidence. The additional PS doses are still
commonly administered for the neutralization of residual UFH, because of the phenomenon known
as “heparin rebound”. This side reaction is associated with serious postoperative bleeding, and is
explained by PS underdosing. Our in vivo study shows that for hemorrhage complications in patients
during cardio-surgical procedures, the antiplatelet activity of excess PS could be responsible. Activated
clotting time or aPTT tests used to monitor the anticoagulant activity of UFH should be interpreted
carefully when PS is administered to restore coagulation, as these tests are insensitive to the antiplatelet
effect of PS, and bleeding may still occur. Our results showed that PS may still exert an antithrombotic
effect even one week after the last administration, which may increase the risk of bleeding, especially
in patients having had previous contact with PS and taking anticoagulants drugs. Importantly, our
conclusions support the results from two different species.
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anti-fXa anti-factor Xa
aPTT activated partial thromboplastin time
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